Background: The gene encoding for uncoupling protein-1 (UCP1) is considered to be a candidate gene for type 2 diabetes because of its role in thermogenesis and energy expenditure. The objective of the study was to examine whether genetic variations in the UCP1 gene are associated with type 2 diabetes and its related traits in Asian Indians.
Introduction

B
rown adipose tissue (BAT), a heat-producing (thermogenic) organ, is now well described as an important site of facultative (shivering) thermogenesis in mammals. 1 Indeed, BAT also contributes to diet-induced thermogenesis. 2 BAT is a very metabolically active tissue, which consists of adipocytes rich in mitochondria and small lipid droplets. 3 Central to the function of BAT is the uncoupling protein (UCP), or thermogenin, which is found exclusively in the mitochondrial inner membrane of brown adipocytes. 4, 5 UCP1, a specifi c mitochondrial proton transporter, uncouples mitochondrial respiration from adenosine triphosphate (ATP) synthesis by mediating H + transport through the inner mitochondrial membrane, 6, 7 thus dissipating the mitochondrial transmembrane H + gradient and producing heat. Although the presence of BAT was thought to be relevant only in small mammals and infants, recent studies have shown that defi ned regions of functionally active BAT are present in healthy adult humans. [8] [9] [10] It is generally accepted that type 2 diabetes results from a complex interplay of genetic and environmental factors infl uencing a number of intermediate traits, such as obesity and fat distribution. 11 Recent studies by the World Health Organization (WHO) report that India has the largest number of diabetic patients in the world. 12 Earlier studies have established that Asian Indians have greater insulin for the presence of all the three polymorphisms, and these were correlated with clinical and metabolic parameters. Informed consent was obtained from each study participant, and use of the samples for genetic studies was approved by the institutional ethics committee.
Measurement of clinical and biochemical variables
Anthropometric measurements, including weight, height, and waist measurements, were obtained using standardized techniques. The body mass index (BMI) was calculated using the formula weight (kg)/height (m 2 ). Blood pressure was recorded in the sitting position in the right arm to the nearest 2 mmHg with a mercury sphygmomanometer (Diamond Deluxe BP apparatus, Pune, India). Two readings were taken 5 min apart and the mean of the two readings was taken as the blood pressure.
FPG (glucose oxidase-peroxidase method), serum cholesterol (cholesterol oxidase-peroxidase-amidopyrine method), serum triglycerides (glycerol phosphate oxidase-peroxidaseamidopyrine method),and high-density lipoprotein cholesterol (HDL-C) (direct method polyethylene glycol-pretreated enzymes) were measured using a Hitachi-912 Autoanalyser (Hitachi, Mannheim, Germany). The intra-and interassay coeffi cient of variation for the biochemical assays ranged between 0.04 and 0.08. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula. 29 Glycosylated hemoglobin (HbA1c) was estimated by highpressure liquid chromatography using the Variant machine (Bio-Rad, Hercules, CA). The intra-and interassay coefficient of variation of HbA1c was <10%. Serum insulin concentration was estimated using Dako kits (Dako, Glostrup, Denmark). The intraassay and the interassay coeffi cients of variation for the insulin assay were 0.06 and 0.09, respectively, and the lower detection limit was 0.5 μIU/mL. Insulin resistance was calculated using the homeostasis assessment model (HOMA-IR) using the formula: Fasting insulin (μIU/ mL) × fasting glucose (mmol/L)/22.5.
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Genotyping
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated venous blood samples were collected from all study subjects, and the genomic DNA was isolated from whole blood by proteinase K digestion followed by phenol-chloroform extraction. The three polymorphisms were genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The primers used to detect the −3826A→G polymorphism in the UCP1 gene were, forward, 5′-CTTGGGTAGTGACAAAGTAT-3′, and reverse, 5′-CCAAAGGGTCAGATTTCTAC-3′; primers used to detect the 5′-UTR A→C were, forward, 5′-AAGTCCCAGCGGAAGA CCGG-3′, and reverse, 5′-GGCAGCAAACCCGATTCCTG-3′. Those used to detect Met229Leu were, forward, 5′-TATCGCTGGATTTGCGCAAAAGCT-3′, and reverse, 5′-CTTGAAGAAAGCCGTTGGTCCTTCG-3′. Different restriction enzymes were used for detecting different polymorphisms. The BclI (New England Biolabs, USA) restriction enzyme for −3826 A→G, 23 BstNI (New England Biolabs, USA) for 5′-UTR A→C, 25 and HindIII (New England Biolabs, US) for Met229Leu. 25 The RFLP products were resolved on a 3% agarose gel electrophoresis. On the basis of the analysis of 350 blind duplicates (~20%), there was 100% concordance resistance, 13 waist-to-hip ratio, 14, 15 and increased susceptibility to diabetes [16] [17] [18] compared to Europeans. This is suggestive of a strong genetic predisposition to type 2 diabetes in Asian Indians. The UCP1 gene is considered to be a candidate gene for type 2 diabetes and its related traits due to its role in thermogenesis and energy expenditure. 2, 3 Our earlier studies have shown that the polymorphisms in the peroxisome proliferator-activated receptor γ coactivator-1 (PPARGC1A), which interacts with peroxisome proliferator-activated receptor γ (PPARG) in the transactivation of the UCP1 gene expression in the BAT, 19 were associated with type 2 diabetes 20 and body fat 21 in Asian Indians. In addition, we have also shown that UCP1 gene polymorphisms were not associated with metabolic syndrome in an Asian Indian population. 22 Hence, the aim of the present study was to examine whether the three relatively frequent polymorphisms in the UCP1 gene, the expression of which is dependent on PPARGC1A, are associated with type 2 diabetes and its related traits. The three polymorphisms comprising the A→G base pair substitution in the promoter region (−3826), an A→C transition in the 5′ untranslated region (UTR) of exon 1, and a Met229Leu (A→T) polymorphism in exon 5 were selected because of their location (promoter and exon), genetic heterogeneities, and the reported associations with type 2 diabetes related traits in different ethnic groups. [23] [24] [25] Given the high prevalence of diabetes and greater insulin resistance in this ethnic group, it is very pertinent to study the variability in UCP1 gene in detail.
Materials and Methods
Study population
The study subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing epidemiology study conducted on a representative population (aged ≥20 years) of Chennai (formerly Madras), the fourth largest city in India with a population of about 4.2 million. The methodology of the study has been published elsewhere. 26 In Phase I of CURES, 26,001 individuals were recruited on the basis of a systematic random sampling technique. Selfreported diabetic subjects on drug treatment of diabetes were classifi ed as "known diabetic subjects." Fasting capillary blood glucose was determined using a One Touch Basic glucometer (Life Scan Johnson & Johnson, Milpitas, CA) in all subjects.
In Phase 2 of CURES, the known diabetic subjects (n = 1529) were invited to visit the center for detailed studies. All subjects with fasting plasma glucose (FPG) levels in the diabetic range based on American Diabetes Association (ADA) fasting criteria 27 underwent oral glucose tolerance tests (OGTT) using 75 grams of oral glucose load (dissolved in 250 mL of water). Subjects who had fasting plasma glucose <6.1 mmol/L (110 mg/dL) and 2-hour plasma glucose value <7.8 mmol/L (140 mg/dL) were categorized as normal glucose tolerance (NGT). Those who were confi rmed by OGTT to have a 2-h plasma glucose value ≥11.1 mmol/L (200 mg/dL) based on the WHO consulting group criteria 28 were labeled as "newly detected diabetic subjects."
For this investigation, a case-control study comprising 810 type 2 diabetic subjects (353 males and 457 females) and 990 NGT subjects (374 males and 616 females) selected from CURES was carried out. All study subjects were genotyped Haplotype frequencies were obtained via the expectationmaximization (EM) algorithm, 31 which equates each genotype frequency to the sum of the probabilities of all possible haplotype confi gurations resulting in that genotype, using the program HAPLOPOP. 32 Having obtained these frequencies, we performed a test of equality of proportion between NGT and type 2 diabetic subjects. The linkage disequilibrium (LD) coeffi cient D′ was estimated from the estimates of haplotypic frequencies using Arlequin (ver 3.0), a software application for population genetics data analysis. 33 We calculated the power of the present study to detect odds ratios (OR) for type 2 diabetes for a range of minor allele frequencies (0.10-0.50) and a sample size of 1800 individuals using the Quanto v1.1.1 (http://hydra.usc.edu/gxe) ( Table 1) .
Results
The clinical characteristics of study subjects with and without type 2 diabetes differed for a number of metabolic traits (Table 2 ). Compared to NGT subjects, the diabetic in the genotyping. Heterozygotes (n = 20) and rare homozygotes (n = 10) for each single-nucleotide polymorphism (SNP) were confi rmed using direct sequencing by ABI 310 genetic analyzer.
Statistical analysis
Statistical Package for Social Sciences for Windows, version 10.0 (SPSS, Inc, Chicago, IL) was used for statistical analysis. The effects of the three polymorphisms on quantitative and categorical variables were analyzed. Allele frequencies were estimated by gene counting. Agreement with Hardy-Weinberg expectations was tested using a chisquared goodness-of-fi t test. One-way analysis of variance (ANOVA) was used to compare groups for continuous variables. The chi-squared test was used to compare the proportions of genotypes or alleles. Risk variables were adjusted for age and sex for comparison between different genotypes. Regression analysis was done using diabetes as dependent variable and the genotypes as independent variables. 
Discussion
Besides several factors contributing to the altered expression of UCP1, the gene locus at 4q31 itself might be a common cause of reduced UCP1 gene activity. Several studies have reported the presence of variations in the 5′-fl anking and the coding regions of the UCP1 gene in different ethnic groups, of which −3826A→G, an A→C transition in the 5′-UTR, and Met229Leu were the most extensively studied polymorphisms. [23] [24] [25] To investigate the hypothesis that defects in the UCP1 gene could be associated with type 2 diabetes and its related metabolic traits, we studied the effects of these three UCP1 polymorphisms in this south Indian population.
We found that the three polymorphisms in the UCP1 gene were not associated with type 2 diabetes in our study population. The lack of association of the −3826A→G polymorphism with type 2 diabetes is in agreement with a study in a Japanese population. 22 The frequency of the variant allele of the −3826A→G polymorphism is 0.38 in NGT and 0.41 in type 2 diabetic subjects. Although the frequency of the variant allele was lower than reported in a Korean population, 34 the frequency in this current study was higher compared to that of the Australian 24 and Danish 35 populations. We observed a signifi cant association of the −3826A→G polymorphism and a marginal association of the 5′-UTR A→C polymorphism with SBP. This is consistent with the fi nding of an association of the chromosome 4 locus, the region where the UCP1 gene is located, with a quantitative trait locus (QTL) for SBP in the Australian Victorian Family Heart Study. 36 It is possible that this polymorphism may not be the main causal site, but an unidentifi ed polymorphism that is in LD with this polymorphism might contribute to this association. Hence, identification of the causal site(s) in the UCP1 gene and functional studies are necessary to delineate the downstream factors involved in the pathogenesis of the disease.
The Met229Leu polymorphism was not associated with type 2 diabetes in our study, which is in contrast to the positive association of this polymorphism with type 2 diabetes in a Japanese population. 25 Given that the Met229 residue of human UCP1 is replaced by Leu in rodents, the Met229Leu polymorphism does not affect the function of the protein.
Hence, the absence of association of this polymorphism with type 2 diabetes and their related traits clearly implicates that the Met229Leu polymorphism may not be a causative variant.
In this study, we failed to show an association of the three UCP1 gene SNPs with type 2 diabetes, which may be due to the following reasons. We found that, with our sample size, we had 80% power to detect ORs >1.25 for type 2 diabetes at the signifi cance level of 0.05. If the true effect sizes are lower, we would not be able to detect them. Although the results are negative, the fi ndings are of relevance, as it is the fi rst study to examine the association of the three UCP1 SNPs with type 2 diabetes in Asian Indians. Importantly, our study was sufficiently powered to test these hypotheses as shown in Table 1 . Thus, a negative fi nding is unlikely to be due to type 2 error. subjects were older (P < 0.0001) and had signifi cantly higher body mass index (BMI) (P < 0.0001), waist circumference (P < 0.0001), systolic and diastolic blood pressure (P < 0.0001), serum cholesterol (P < 0.0001), and triglycerides (P < 0.0001).
The genotype frequencies of the three polymorphisms were in Hardy-Weinberg equilibrium (P > 0.05). The genotype and allele frequencies of the three polymorphisms of the UCP1 gene were not associated with type 2 diabetes (Table 3) . However, phenotype-genotype analysis showed that NGT subjects with AG genotype of the −3826A→G polymorphism had signifi cantly higher systolic blood pressure (SBP) compared to those with the AA genotype (AA, 117 ± 14 mmHg vs. AG, 121 ± 18 mmHg, P = 0.004). Similarly, the SBP was signifi cantly higher in the NGT subjects with the CC genotype of the 5′-UTR A→C polymorphism compared to those with the AA genotype (AA, 119 ± 17 mmHg vs. CC 126 ± 20 mmHg, P = 0.05). None of the clinical and biochemical fi ndings was statistically signifi cant among the genotypes of the Met229Leu polymorphism.
The pairwise LD value between the loci −3826A→G and 5′-UTR A→C was 0.3956 (P < 0.0001), 5′-UTR A→C and Met229Leu was 0.8698 (P < 0.0001), and −3826A→G and Met229Leu was 0.4643 (P < 0.0001) in the type 2 diabetic subjects. Similarly, the pairwise LD value between the loci −3826A→G and 5′-UTR A→C was 0.4981 (P < 0.0001), 5′-UTR A→C and Met229Leu was 0.7559 (P < 0.0001), and −3826A→G and Met229Leu was 0.6236 (P < 0.0001) in the NGT subjects. The frequency of the A-C-Met (−3826A→G-5′-UTR A→C-Met229Leu) haplotype in the type 2 diabetic subjects was 2.67% and the frequency in the NGT subjects was 1.45% (P < 0.01). Logistic regression analysis revealed that the OR for type 2 diabetes for the individuals carrying However, the haplotypes show interesting results. In the present study, the subjects carrying the A-C-Met (−3826A→G-5′-UTR A→C-Met229Leu) haplotype had 1.82 times higher risk for developing type 2 diabetes. A study in 570 subjects by Mori et al. 25 has shown that the 5′-UTR A→C and Met229Leu polymorphisms of UCP1 are in LD and could be one of the diabetes-associated polymorphisms. Our study further confi rms this fi nding from the supportive evidence of a large sample size of 810 type 2 diabetic subjects and 990 NGT subjects from the CURES.
Population stratifi cation can be a confounding factor in genetic case-control or association studies. A way to test for stratifi cation is by genotyping a number of markers that are not related to each other and also to the trait under investigation. In a recent study, it was shown that signifi cant differences in allele and genotype frequencies between northern and southern Indian populations were observed for the −3826 A/G polymorphism in the UCP1 gene. 37 It has also been shown that there is signifi cant diversity in allele frequencies at many autosomal loci within different castes in South India. 38 A case-control study at six unlinked marker loci believed to be unrelated to the disease under study, but known to have allelic diversity among different populations, was carried out. 39 The allele frequency difference between NGT and type 2 diabetic subjects was not statistically significant at any of the six loci, indicating that the fi ndings in this study are not an artifact of population substructuring.
In summary, the A-C-Met haplotype of the UCP1 gene is signifi cantly associated with type 2 diabetes in Asian Indians, despite the fact that the three UCP1 polymorphisms failed to show an association with type 2 diabetes independently. Due to the polygenic nature of the common forms of type 2 diabetes, it is necessary to examine the potential interactions of the UCP1 and other gene polymorphisms implicated in adaptive thermogenesis to see if they have additive or synergistic impact on the susceptibility to type 2 diabetes.
